Dianthus Therapeutics (DNTH) Consolidated Net Income (2017 - 2025)
Historic Consolidated Net Income for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$36.6 million.
- Dianthus Therapeutics' Consolidated Net Income fell 4390.1% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 8702.54%. This contributed to the annual value of -$84.5 million for FY2024, which is 9465.33% down from last year.
- Latest data reveals that Dianthus Therapeutics reported Consolidated Net Income of -$36.6 million as of Q3 2025, which was down 4390.1% from -$31.5 million recorded in Q2 2025.
- Dianthus Therapeutics' Consolidated Net Income's 5-year high stood at -$7.1 million during Q1 2023, with a 5-year trough of -$36.6 million in Q3 2025.
- Its 4-year average for Consolidated Net Income is -$18.7 million, with a median of -$14.7 million in 2023.
- Per our database at Business Quant, Dianthus Therapeutics' Consolidated Net Income plummeted by 456.58% in 2023 and then plummeted by 16565.83% in 2024.
- Dianthus Therapeutics' Consolidated Net Income (Quarter) stood at -$10.1 million in 2022, then dropped by 4.57% to -$10.5 million in 2023, then tumbled by 165.66% to -$27.9 million in 2024, then tumbled by 31.17% to -$36.6 million in 2025.
- Its last three reported values are -$36.6 million in Q3 2025, -$31.5 million for Q2 2025, and -$29.4 million during Q1 2025.